



Contacts:

Matt Niloff
Sr. Director of Products & Sales
Xcellerex, Inc.
508-683-2296

**Cellon, S.A. to represent Xcellerex
in key European markets**

Marlborough, MA, July 1, 2008 – Xcellerex, Inc. announced today that Cellon, S.A. of Luxembourg will be the exclusive technical sales representative for Xcellerex's industry leading line of XDR single-use bioreactors and XDM/XTM mixing systems in several key European markets. The Xcellerex/Cellon agreement covers UK, France, Germany, Belgium, Netherlands, Ireland, Switzerland, Austria and Luxembourg.

"Biopharm and vaccine customers around the world are enthusiastically embracing the XDR as the best fully-integrated, GMP single-use bioreactor available, and we are actively adding leading technical sales organizations in local markets to address customer demand. Cellon has distinguished itself as a highly-respected, technically capable resource for developers of vaccines and biotherapeutics, and we are thrilled to have them as a partner," said John Chickosky, Chief Operating Officer at Xcellerex.

Chickosky added, "The Cellon team enjoys deep relationships with many of the top biopharm and vaccine technical organizations in Europe, especially in the area of cell culture. They are a natural fit for Xcellerex and our European customers are already benefiting from their involvement."

Cellon Managing Director Richard Fry commented, "Xcellerex is a perfect fit for Cellon. We have been reviewing emerging single-use technologies and believe that Xcellerex represents the path that makes the most sense for the biopharmaceutical industry and our customers. The combination of outstanding process performance, flexibility and control with astonishing speed, ease-of-use and institutional knowledge makes their systems the benchmark for the industry."

-more-

About Xcellerex, Inc.

Xcellerex is built around a unique biomanufacturing platform that features the innovative application of single-use component technology. Xcellerex offers a suite of world-class products and services to support the adoption of its platform. These include the XDR line of GMP single-use bioreactors, PDMax™ high-throughput process development and optimization services, and proven GMP manufacturing operated by an experienced CMC team. The company also is also developing its own portfolio of vaccines and therapeutics that are enabled by its FlexFactory biomanufacturing platform, development and CMC capabilities. In addition, Xcellerex actively seeks creative partnerships to facilitate access to the platform. Learn more at www.xcellerex.com

About Cellon, S.A.

Since 1987, Cellon has specialized in providing technically advantaged products and services to the vaccine production and bioprocessing industries. Areas of expertise include mammalian cell culture processes and the storage & transport of sterile liquids. Cellon's success is built upon deep collaborative relationships with customers, which enable an optimized matching of customer need with technical solution. Cellon is headquartered in Luxembourg.

For additional information, please contact:

Xcellerex, Inc.

Matt Niloff
Sr. Director of Products & Sales

508-683-2296
mniloff@xcellerex.com
www.xcellerex.com

Cellon, S.A.

Richard Fry
Managing Director

(352) 2633731
richard-fry.cellon@gms.lu
www.cellon.lu

###

About XDR GMP Single-User Bioreactors

With a fully-integrated vessel and process control unit and in-house experts that operate them everyday, XDR single-use bioreactors from Xcellerex are the only GMP compliant stirred-tank systems that offer true plug-and-play, process-ready performance on arrival. XDRs deliver scalable performance from 40L to 2000L. 5:1 turndown means XDRs can operate at 20% of nominal volume, doing the work of multiple reactors. XDRs can be delivered and operational in 12 weeks.

More: www.xcellerex.com/xdr